Senseonics (NYSE:SENS) today priced stock and debt offerings worth a total of at least $107 million. Germantown, Md.-based Senseonics, which developed the Eversense implantable CGM, announced the offerings yesterday. Get the full story at our sister site, Drug Delivery Business News
Diabetes
Welcome to MassDevice's Diabetes Hub, your resource for the latest news in diabetes technology. Stay informed about the innovations and business news shaping the diabetes device industry.
Here are top diabetes features from MassDevice and its sister publications (and scroll down to read the latest diabetes device news from MassDevice):
+ These diabetes devices are set to launch in 2024
+ The top IVD and diabetes tech stories of 2023
+ How Dexcom designed a new “life-changing” sensor for even more people with diabetes
+ Embecta CEO sees GLP-1 opportunities as company progresses on insulin patch pump
+ The 10 biggest diabetes tech stories from 2023
Latest Diabetes News
Report: Literal killer app prompted Medtronic MiniMed recall
Two years ago, researchers discovered vulnerabilities in Medtronic’s MiniMed and MiniMed Paradigm insulin pump lines that could allow hackers to remotely withhold insulin or trigger a potentially lethal overdose. But after months of negotiations with Medtronic and regulators with no fix forthcoming, the researchers decided to build a smartphone app that could show how the […]
Senseonics slides on stock, debt offerings, Q2 prelims
Senseonics (NYSE:SENS) shares are off nearly -7% today after the continuous glucose monitor maker revealed plans for a stock and debt offerings and released its preliminary second-quarter sales numbers. Germantown, Md.-based Senseonics, which developed the Eversense implantable CGM, said it plans to float $25 million in stock (plus a 30-day, $3.8 million underwriters option) and $80 […]
Nemaura bids for de novo clearance from FDA for SugarBEAT glucose monitor
Nemaura Medical (NSDQ:NMRD) this week said it submitted a De Novo medical device applications to the FDA for its SugarBEAT non-invasive glucose monitor. The Loughborough, England-based company recently successfully completed clinical studies and two summative human factors usability studies needed to support De Novo submission. Get the full story on our sister site, Drug Delivery Business.
Valeritas touts study results
Valeritas (NSDQ:VLRX) today announced the results of a study that showed patients using its V-Go wearable insulin delivery device needed less insulin, had lower A1c levels and reduced diabetes-related medication cost compared with patients using multiple daily injection (MDI) therapy. The retrospective study by the Bridgewater, N.J.-based company used information from the HealthCore Integrated Research Database (HIRD). […]
AgaMatrix raises $56m for WaveForm CGM
AgaMatrix said today that it brought in a $56 million funding round for the eponymous continuous glucose monitor its WaveForm Technologies subsidiary is developing. The round, which includes $6 million from new and existing backers and $50 million in senior debt financing from Perceptive Advisors, is slated for paying down debt and increasing production capacity, […]
Biocorp, Sanofi ink €4m Mallya sensor deal
Biocorp (PAR:ALCOR) said today that it inked a deal with pharma giant Sanofi (NYSE:SNY) to integrate its Mallya sensor into Sanofi’s diabetes management platform. Issoire, France-based Biocorp’s Mallya is designed to clip to an injection pen to automatically log and transmit dosage data. The deal calls for Sanofi to pay Biocorp €4 million, or about $4.5 million, “to […]
Livongo Health files for $100m IPO
Livongo Health last week filed for an initial public offering worth $100 million for the digital health platform it developed to treat chronic diseases. The Mountain View, Calif.-based company’s initial focus on diabetes involves a smart, cellular-connected glucose meter, automatically-delivered testing materials, real-time coaching and full-time monitoring. The system personalizes messages based on each glucose reading […]
Apple stores to sell One Drop glucose monitor
Apple (NSDQ:AAPL) is reportedly selling One Drop blood glucose monitors in a small number of its namesake stores in the U.S. One Drop is a compact blood glucose monitor that is compatible with the iOS Health app and the Apple Watch. The device is connected through Bluetooth and draws a small amount of blood to measure […]
Medtronic recalls MiniMed pump models on cybersecurity risk
Medtronic (NYSE:MDT) today recalled two models of its MiniMed insulin pumps after researchers discovered cybersecurity risks that could allow a hacker to take control of the devices. The recall affects 11 models in Fridley, Minn.-based Medtronic’s line of MiniMed 508, MiniMed Paradigm and MiniMed Paradigm Veo pumps, according to the FDA. Medtronic said the pumps are […]
Inside Insulet’s pivotal year with CEO Shacey Petrovic
It’s been a busy year at Insulet (NSDQ:PODD). The diabetes tech company welcomed a new CEO, launched its first new product in six years and officially opened its $200 million global headquarters – all in the first half of 2019. That’s all the result of years of rapid growth for Insulet, chief executive Shacey Petrovic said in […]